Korea's Celltrion Cuts Deal With Jordan-based Hikma To Sell Its Biosimilars In The Middle East, Africa

SEOUL - Days after finalizing a deal to sell biosimilar therapeutic antibodies in Israel, Korea's Celltrion has signed a similar agreement with Jordan-based Hikma Pharmaceuticals to market the products across 17 Middle East and Northwestern African countries